Exacerbation severity and frequency are crucial for the prognosis of COPD, but also appear to have a major impact on the course of comorbidities. There is a growing body of evidence showing that COPD patients are at increased risk of cardiovascular events, with the frequency and severity of exacerbations being important predictors. Optimal treatment of COPD also appears to reduce the risk of concomitant diseases. Depending on the situation, it may make sense to extend dual bronchodilation with inhaled steroids or roflumilast as an add-on.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Cutaneous Crohn's disease
Effective alternative to TNF inhibitors
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Benralizumab in a patient with asthma and EGPA
When the biologic has a counterproductive effect
- Brain atrophy and MS
Brain atrophy correlates with disability progression in MS
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Diabetes mellitus
Treatment of comorbidities in older people
- Pulmonary sarcoidosis
Prednisone vs. MTX: a draw after 24 weeks
- Friedreich's ataxia